- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02266550
Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers
October 16, 2014 updated by: Boehringer Ingelheim
Investigation of Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS After Administration of a Single Oral Dose of 25 mg [14C]-BIIL 284 BS in 6 Healthy Volunteers
The aims of this phase I study are to define the metabolism, excretion and pharmacokinetics of [14C]-BIIL 284 BS after administration of a single oral dose of 25 mg [14C]-BIIL 284 BS in 6 healthy volunteers.
Tolerability was also assessed.
Study Overview
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male volunteers, range from 30 to 55 years of age inclusive
- Body weight between 50 and 100 kg and within ± 20% of ideal body weight
- No clinically significant abnormal physical findings at the screening examination which would interfere with the objective of the study
- No clinically relevant abnormalities in the results of laboratory screening evaluation
- Normal ECG
- Normal Blood pressure (between 100 to 150 mmHg systolic and 50 to 90 mmHg diastolic) and heart rate (between 50 to 90 beats per minute)
- Able to communicate well with the investigator and to comply with the requirements of the entire study
- Provision of written informed consent to participate as shown by a signature on the volunteer consent form
- Non-smokers
Exclusion Criteria:
- Medical examination or laboratory test results that are judged by the clinical investigator to differ significantly from normal clinical values
- Known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Current disease of the central nervous system (such as epilepsy) or with psychiatric disorders)
- Known history of orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- Intake of any drugs which might influence the results of the trial during the week previous to the start of the study
- Administration of any investigational drug in the period 3 months before entry to the study (4 months if the previous drug was a new chemical entity)
- A need for any medication within the two weeks before dosing
- Existence of any surgical or medical condition which, in the judgement of the clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug (e.g. renal or hepatic impairments)
- Presence of clinically relevant history of allergy/hypersensitivity (including drug allergy)
- Blood loss or donation within the last 12 weeks (≥ 400 ml)
- Serious adverse reaction/hypersensitivity to any drug
- Objection by the subject's general practitioner to his/her patient's participation in the study
- Positive results for drug screening as listed in the protocol, positive results for hepatitis B surface antigen, Anti hepatitis B core antibodies, Anti hepatitis C virus antibodies and human immunodeficiency test, Glucose 6 - Phosphate Dehydrogenase
- Inability to communicate or co-operate with the investigator due to language problem, poor mental development or impaired cerebral function
- Administration of radiolabelled substance or exposure to significant radiation (e.g. serial X-ray, or CT scans, barium meal, etc) within the past 12 months
- History of recent drug abuse
- Volunteers who drink more than 4 units of alcohol per day and/or have been consuming alcohol during the 24 hours before dosing
- Participation in excessive physical activities (e.g. competitive sports) within the last week before the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rates and routes of excretion of total radioactivity
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Concentration of [14C] radioactivity in blood
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Concentration of [14C] radioactivity in excreta (urine, faeces)
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Maximum concentration of the analytes in plasma (Cmax)
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Time to reach Cmax (tmax)
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Terminal half-life (t1/2)
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Mean residence time (MRT)
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Area under the drug concentration-time curve extrapolated from zero to infinity (AUC0-inf)
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Apparent clearance (CL/f)
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Volume of distribution (Vd/f)
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Nature of metabolites in plasma
Time Frame: up to 8 hours after drug administration
|
up to 8 hours after drug administration
|
Nature of metabolites in urine
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Nature of metabolites in faeces
Time Frame: up to 48 hours after drug administration
|
up to 48 hours after drug administration
|
Excretion balance on the basis of the [14C] radioactivity in urine and faeces
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with clinically significant changes in laboratory parameters
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Number of subjects with clinically significant findings in physical examination
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Number of subjects with clinically significant changes in vital signs
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Number of subjects with clinically significant findings in 12-lead electrocardiogram
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Number of subjects with adverse events
Time Frame: up to 216 hours after drug administration
|
up to 216 hours after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 1999
Primary Completion (Actual)
October 1, 1999
Study Registration Dates
First Submitted
October 16, 2014
First Submitted That Met QC Criteria
October 16, 2014
First Posted (Estimate)
October 17, 2014
Study Record Updates
Last Update Posted (Estimate)
October 17, 2014
Last Update Submitted That Met QC Criteria
October 16, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 543.16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on [14C] BILL 284 BS
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedArthritis, Rheumatoid
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
Boehringer IngelheimCompleted